Ocrelizumab (Ocrevus®) has been accepted for use within NHS Scotland, for the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.
In a randomised, double-blind, phase III study, the risk of disability progression was significantly reduced in patients who received ocrelizumab compared with placebo.
See https://www.scottishmedicines.org.uk/medicines-advice/ocrelizumab-ocrevus-full-smc2223/
Richard Erwin, General Manager, Roche UK, said
Following many years of dedication and hard work by our scientists and the wider scientific community, today’s news is a landmark in the treatment of multiple sclerosis. People in Scotland with early, primary progressive multiple sclerosis (PPMS) will now be able to benefit from the first ever licensed treatment on the Scottish NHS. This underlines our commitment to support people in Scotland, across all of the diseases we cover, to live longer and healthier lives. We are proud to have again worked together with key Scottish stakeholders to make this happen.
